Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Closed for Enrollment
-
A Phase 2a Study of TPN-101 in Patients with Progressive Supranuclear Palsy (Transposon PSP)
Rochester, Minn.
The primary objective of this study is to asssess the safety and tolerability of TPN-101 in patients with progressive supranuclear palsy (PSP).
-
A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy
Jacksonville, Fla.,
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.
The purpose of this study is to assess the effectiveness, safety, tolerability, and drug/body interactions of ABBV-8E12 for the treatment of patients who have progressive supranuclear palsy.
-
A Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered NIO752 in Participants With Progressive Supranuclear Palsy
Rochester, Minn.
The main purpose of this multi-center, randomized, placebo-controlled, participant, investigator and sponsor blinded study is to evaluate the safety, tolerability and pharmacokinetics of NIO752 in Progressive Supranuclear Palsy (PSP) participants when administered intrathecally once every 4 weeks (four administrations) in a range of escalating doses.
-
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
Jacksonville, Fla.,
Scottsdale/Phoenix, Ariz.,
Rochester, Minn.
The purpose of this study is to assess the long-term safety and effectiveness of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).
-
Clinical and Genetic Factors Associated with Survival and Other Outcomes in Parkinson's Disease
Rochester, Minn.
The purpose of this study is to answer the question, "Do baseline clinical and/or genetic factors predict survival, and other outcomes (e.g., dementia, hallucinations, wheelchair use) in Parkinson's disease (PD)?"
.